Cancer-A-Gogo

  • Home
  • About Cancer-A-Gogo
  • UK Affiliates
  • Nascent Therapies
  • News / Favorites
  • Donate Now

From Dr. Sheila Singh, pediatric neurosurgeon, McMaster University

From Dr. Sheila Singh,
pediatric neurosurgeon-researcher
McMaster University

I wanted to share with you our recently published Cancer Cell paper, where our CRISPR screens of patient-derived lines found a new, targetable metabolic vulnerability in myc-amplified childhood medulloblastoma. We repurposed a Bayer DHODH inhibitor which is in clinical trials already toward our brain cancer models, and found huge efficacy.. as did two other groups who co-published in Cancer Cell a month before us.. both groups from Harvard, one showing the same efficacy in IDH mutant glioma and the other in DIPG. This trifecta speaks well for highly reproducible data from 3 strong brain cancer research groups!! Cancer Cell followed up with an editorial that featured the collective impact of all 3 papers:

Summary

MYC-driven medulloblastoma (MB) is an aggressive pediatric brain tumorcharacterized by therapy resistance and disease recurrence. Here, we integrated data from unbiased genetic screening and metabolomic profiling to identify multiple cancer-selective metabolic vulnerabilities in MYC-driven MB tumor cells, which are amenable to therapeutic targeting. Among these targets, dihydroorotate dehydrogenase (DHODH), an enzyme that catalyzes de novo pyrimidine biosynthesis, emerged as a favorable candidate for therapeutic targeting. Mechanistically, DHODH inhibition acts on target, leading to uridine metabolite scarcity and hyperlipidemia, accompanied by reduced protein O-GlcNAcylation and c-Myc degradation. Pyrimidine starvation evokes a metabolic stress response that leads to cell-cycle arrest and apoptosis. We further show that an orally available small-molecule DHODH inhibitor demonstrates potent mono-therapeutic efficacy against patient-derived MB xenografts in vivo. The reprogramming of pyrimidine metabolism in MYC-driven medulloblastoma represents an unappreciated therapeutic strategy and a potential new class of treatments with stronger cancer selectivity and fewer neurotoxic sequelae.

We are asking for £1 (pound) from every Briton (67 million) and $1 (dollar) from every American (340 million) to fund cutting edge cancer research in the UK and US respectively. All monies go directly to research (labs, scientists, doctors) with no overhead deducted.
For UK Donations click here
 
For US Donations click here
 

Contact US

Please contact us at info@canceragogo.com

Copyright © 2025 · Cancer-A-Gogo · We are a 501C3 IRS approved charity • Log in